Press
Releases

Press Releases

April 29, 2021
Altimmune to Present at Upcoming Scientific Conferences
GAITHERSBURG, Md. , April 29, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will be presenting at two scientific conferences in May 2021 .
April 1, 2021
Altimmune Reports Data from its Phase 1b Clinical Trial of NasoShield™
GAITHERSBURG, Md. , April 01, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, reported clinical data today on its NasoShield intranasal anthrax vaccine candidate. The Phase 1b trial evaluated the safety and immunogenicity of one and two-dose
March 15, 2021
AdCOVID™, Altimmune’s Single Dose, Intranasal COVID-19 Vaccine Candidate, Prevents SARS-CoV-2-induced Disease and Blocks Viral Replication in Preclinical Studies of SARS-CoV-2 Infection
New Findings from Ongoing Collaborations with University of Alabama at Birmingham  and Saint Louis University Studies Show Complete Protection Against Lethal Challenge  and Dramatic Reduction in Viral Replication Systemic and Mucosal Antibody Responses Durable for at Least 6 Months GAITHERSBURG,
March 12, 2021
Altimmune Expands AdCOVID™ Manufacturing Collaboration with Lonza
Lonza to Commission a Dedicated Suite for Clinical and Commercial Supply of Altimmune’s COVID-19 Vaccine Candidate at its Houston Facility GAITHERSBURG, Md. and BASEL, Switzerland , March 12, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today
March 8, 2021
Altimmune to Present at Upcoming Conferences
GAITHERSBURG, Md. , March 08, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the management team will present during a fireside chat at the H.C. Wainwright Global Life Sciences Conference , being held Mar 9-10,
February 22, 2021
Altimmune To Announce Year End 2020 Financial Results on February 25, 2021
GAITHERSBURG, Md. , Feb. 22, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its full year 2020 financial results on Thursday, February 25 th , 2021. Altimmune management will host a conference call for
February 17, 2021
Altimmune Announces FDA Clearance of AdCOVID™ IND Application
Enrollment in Phase 1 clinical trial of single-dose, needle-free, intranasal COVID-19 vaccine candidate set to begin in the coming week GAITHERSBURG, Md. , Feb. 17, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the U.S.
 

Investor Contact

Will Brown
Chief Financial Officer

Email: wbrown@altimmune.com

 

Email Alerts

Automatically receive Altimmune, Inc. financial information by e-mail

Subscribe